Last Modified Date: February 22, 2018
Celgene started 2018 with billion dollar acquisitions of two companies: Impact Biomedicines and Juno Therapeutics.
Impact Biomedicines was acquired for its fedratinib asset, which has now been passed from private company to pharma giant twice over.
Juno Therapeutics was acquired for its engineered T cell therapies, a deal that was hardly surprising in light of Novartis' success with Kymriah, the acquisition of Kite Pharma by Gilead Sciences, and the fact that Celgene already owned equity in Juno.
With these new rockstars in its stable, Celgene must now focus on bringing them successfully to market while keeping an eye out for other promising assets to add to its pipeline.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 12 042M
Therapeutic Focus: Hematology and Liquid Tumors, Inflammation and Immunology, Solid Tumors
Figure 1. Celgene Corporation. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)
ACQUISITION OF JUNO THERAPEUTICS FOR CAR-T AND TCR ASSETS
Total Size: USD 9 000M | Therapeutic Area: Hematology and Liquid Tumors | Date: January 2018
ACQUISITION OF IMPACT BIOMEDICINES FOR HEMATOLOGY ASSET
Total Size: USD 2 250M | Upfront: USD 1 100M | Therapeutic Area: Hematology and Liquid Tumors | Date: January 2018
COLLABORATION WITH NIMBUS THERAPEUTICS FOR TYK2 AND STING ANTAGONIST ASSETS
Therapeutic Area: Inflammation and Immunology | Date: October 2017
Figure 2. Celgene Corporation. R&D Pipeline at Present (February 2018)
TRIPHASE ACCELERATOR PARTNERED PROTEASOME INHIBITOR
Disease Area: Solid Tumors | Status: Glioblastoma Combination Therapy Phase III | Malignant Glioma and Glioblastoma Combination Therapy Phase II
ACQUIRED RECEPTOS SELECTIVE SPHINGOSINE 1-PHOSPHATE 1 AND 5 RECEPTOR MODULATOR
LYCERA PARTNERED ROR-GAMMA AGONIST COMPOUNDS